Funding Rounds
Stalicla

Stalicla Series B (2024, $13M)

Stalicla

Precision medicine developer for neuropsychiatric and neurological disorders.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series B

Raised Amount: $13.60M

Investors